ClinicalTrials.gg
CompletedNCT05599191CALM-1Updated Jul 14, 2026

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

A Phase 3 interventional study of BLU-5937 and Placebo in Cough and Refractory Chronic Cough, sponsored by Bellus Health Inc. - a GSK company. Completed at 200 sites in 15 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Primary conditionChronic CoughRegistry: CoughReclassifiedWhy we changed it
Registry
Cough — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Cough
Why
  1. The study's listed conditions name Chronic Cough, a narrower term within Cough.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
957
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Chronic Cough · United States.

Enrollment
3rd of 37
957 · median 50
Started
2022
with 4 others
Phase 3
7 of 44
none open now
Registered
33rd of 44
by date
Lead sponsor
4 of 44
Bellus Health Inc. - a GSK company

Among the 44 studies in Chronic Cough with a site in United States, this one is the 3rd largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 33rd registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Chronic Cough with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Read the detailed description

The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 12 weeks.

03

Conditions studied

  • Cough
  • Refractory Chronic Cough

Keywords

  • Respiration Disorders
  • Respiratory Tract Diseases
  • Signs and Symptoms, Respiratory
  • Cough
  • Chronic Cough
04

In context

Chronic Cough Reclassified

142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.

This study's enrollment of 957 is above the median of 60 across 104 interventional studies indexed under Chronic Cough.

Browse Chronic Cough studies →

Lead sponsor

Bellus Health Inc. - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 4 (36%) have results posted.

First submitted before Bellus Health Inc. became part of GlaxoSmithKline.

Compared within Chronic Cough, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cough. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed
  • chronic cough (including unexplained chronic cough) for at least one year
  • Women of must use a highly effective method during the study and for at least 14 days after the last dose

Exclusion criteria

Exclusion Criteria:

  • Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history
  • Diagnosis of , bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment
  • Respiratory tract infection within 4 weeks before screening
  • Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
  • History of in the last 5 years
  • History of alcohol or drug abuse within the last 3 years
  • Has a positive serologic test for (HIV), virus surface antigen, or virus.
  • Previous participation in a BLU-5937 trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
957 participants (actual)

Study arms

  • Experimental
    BLU-5937 25 mg

    BLU-5937 oral dose 25 mg twice a day.

    Drug: BLU-5937

  • Experimental
    BLU-5937 50 mg

    BLU-5937 oral dose 50 mg twice a day.

    Drug: BLU-5937

  • Placebo comparator
    Placebo

    Matching Placebo for BLU-5937 oral dose twice a day.

    Drug: Placebo

Interventions

  • Oral administration of BLU-5937 Tablets

    Also known as: Camlipixant

  • DrugPlacebo

    Oral administration of matching placebo for BLU-5937 Tablets

07

What researchers measure

Primary outcomes

  1. 24-Hour Cough Frequency

    Assessed using an ambulatory cough monitor

    Time frame: Week 12

  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 52

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator.

    Time frame: Up to Week 52

  3. Number of Participants with Adverse Events of Medical Interest (AEMIs) up to Week 52

    An AEMI is an event of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring is appropriate. The following are AEMIs for this study: taste disturbance, oral hypoesthesia, oral paresthesia, and new or worsening findings of the cornea.

    Time frame: Up to Week 52

  4. Number of Participants with Study Treatment Discontinuation due to AEs and SAEs up to Week 52

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator.

    Time frame: Up to Week 52

  5. Number of Participants with AEs and SAEs Leading to Study Withdrawal up to Week 52

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator.

    Time frame: Up to Week 52

  6. Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (millimeters of mercury [mm Hg]) at Week 52

    Time frame: Baseline, Week 52

  7. Change from Baseline in Vital Sign: Pulse (beats per minute) at Week 52

    Time frame: Baseline, Week 52

  8. Change from Baseline in Vital Sign: Respiratory Rate (breaths per minute) at Week 52

    Time frame: Baseline, Week 52

  9. Change from Baseline in Vital Sign: Body Temperature (degrees Celsius) at Week 52

    Time frame: Baseline, Week 52

  10. Change from Baseline in Vital Sign: Weight (kilograms [kg]) at Week 52

    Time frame: Baseline, Week 52

  11. Change from Baseline in Male Reproductive Hormone: Total Testosterone (nanomoles per liter [nmol/L]) at Week 52

    Time frame: Baseline, Week 52

  12. Change from Baseline in Male Reproductive Hormones: Follicle-Stimulating Hormone [FSH] and Luteinizing Hormone [LH] (international units per liter [IU/L]) at Week 52

    Time frame: Baseline, Week 52

  13. Change from Baseline in Male Reproductive Hormone: Inhibin B (nanograms per liter [ng/L]) at Week 52

    Time frame: Baseline, Week 52

  14. Change from Baseline in Hematology Parameter: Red Blood Cell (RBC) Count (10^12 cells per liter) at Week 52

    Time frame: Baseline, Week 52

  15. Change from Baseline in Hematology Parameters: Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) (grams per liter [g/L]) at Week 52

    Time frame: Baseline, Week 52

  16. Change from Baseline in Hematology Parameter: Hematocrit (percentage) at Week 52

    Time frame: Baseline, Week 52

  17. Change from Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) (femtoliters [fL]) at Week 52

    Time frame: Baseline, Week 52

  18. Change from Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) (picograms per cell [pg/cell]) at Week 52

    Time frame: Baseline, Week 52

  19. Change from Baseline in Hematology Parameter: Red Cell Distribution Width (RDW) (percentage) at Week 52

    Time frame: Baseline, Week 52

  20. Change from Baseline in Hematology Parameters: White Blood Cell (WBC) Count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and Platelet Count (10^9 cells per liter) at Week 52

    Time frame: Baseline, Week 52

  21. Change from Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma-Glutamyl Transferase (GGT) (units per liter [U/L]) at Week 52

    Time frame: Baseline, Week 52

  22. Change from Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase (ALP) and Creatine Kinase (CK) (international units per liter [IU/L]) at Week 52

    Time frame: Baseline, Week 52

  23. Change from Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct and Indirect Bilirubin, and Creatinine (micromoles per liter) at Week 52

    Time frame: Baseline, Week 52

  24. Change from Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Calcium, Magnesium, Bicarbonate, Glucose, and Blood Urea Nitrogen (BUN) (millimoles per liter [mmol/L]) at Week 52

    Time frame: Baseline, Week 52

  25. Change from Baseline in Clinical Chemistry Parameters: Protein and Albumin (grams per liter [g/L]) at Week 52

    Time frame: Baseline, Week 52

  26. Change from Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR) (milliliters per minute per 1.73 meters squared [mL/min/1.73 m^2]) at Week 52

    Time frame: Baseline, Week 52

  27. Change from Baseline in Clinical Chemistry Parameters: Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) (seconds) at Week 52

    Time frame: Baseline, Week 52

  28. Change from Baseline in Electrocardiogram (ECG) Value: Heart Rate (beats per minute) at Week 52

    Time frame: Baseline, Week 52

  29. Change from Baseline in ECG Value: PR Interval, QT Interval, RR Interval, QRS Interval, and Corrected QT Interval Using Fridericia's Formula (QTcF) (milliseconds) at Week 52

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Change from Baseline in Cough Severity Visual Analogue Scale at Week 12

    Assessed by Cough Severity Visual Analogue Scale \[VAS\] by the participant on a 100 mm visual analogue scale where higher scores indicate greater severity.

    Time frame: Baseline, Week 12

  2. Percentage of Participants With Greater than or Equal to (>=) 30 mm Reduction From Baseline in Cough Severity Visual Analogue Scale at Week 12

    Assessed by Cough Severity Visual Analogue Scale \[VAS\] by the participant on a 100 mm visual analogue scale where higher scores indicate greater severity.

    Time frame: Baseline, Week 12

  3. Awake Cough Frequency at Week 12

    Assessed using an ambulatory cough monitor

    Time frame: Week 12

  4. Percentage of Participants With >= 30 percent (%) Reduction From Baseline in 24-Hour Cough Frequency at Week 12

    Assessed using an ambulatory cough monitor

    Time frame: Baseline, Week 12

  5. Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 12

    The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the impact of cough on 3 domains: physical, psychological, and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life.

    Time frame: Baseline, Week 12

  6. Percentage of Participants With a >= 1.3-point Increase From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 12

    The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the impact of cough on 3 domains: physical, psychological, and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life.

    Time frame: Baseline, Week 12

  7. Change from Baseline in the Chronic Cough Diary (CCD) Score at Week 12

    The CCD is a participant-completed daily diary used to assess chronic cough. The CCD score ranges from 0 to 16, with a higher score indicating worse symptoms.

    Time frame: Baseline, Week 12

  8. Percentage of Participants with CCD Response at Week 12

    Percentage of participants with CCD response will be summarized.

    Time frame: Week 12

08

Study locations

200 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Litchfield Park, Arizona 85340, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85248, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Encinitas, California 92024, United States
  • GSK Investigational Site
    Mission Viejo, California 92691, United States
  • GSK Investigational Site
    Paramount, California 90723, United States
  • GSK Investigational Site
    Roseville, California 95661, United States
  • GSK Investigational Site
    Aurora, Colorado 80012, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80923, United States
  • GSK Investigational Site
    Clearwater, Florida 33756, United States
  • GSK Investigational Site
    Gainesville, Florida 32608, United States
  • GSK Investigational Site
    Miami, Florida 15801, United States
  • GSK Investigational Site
    Miami, Florida 33155, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Miami, Florida 33186, United States
  • GSK Investigational Site
    Orlando, Florida 32713, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30046, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    Oak Lawn, Illinois 60453, United States
  • GSK Investigational Site
    Ames, Iowa 50010, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Kansas City, Kansas 66160, United States
  • GSK Investigational Site
    Topeka, Kansas 66606, United States
  • GSK Investigational Site
    Wichita, Kansas 67214, United States
  • GSK Investigational Site
    Crowley, Louisiana 70526, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71115, United States
  • GSK Investigational Site
    Annapolis, Maryland 21404, United States
  • GSK Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48109, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    Columbia, Missouri 65203, United States
  • GSK Investigational Site
    St Louis, Missouri 63110, United States
  • GSK Investigational Site
    St Louis, Missouri 63141, United States
  • GSK Investigational Site
    Missoula, Montana 59808, United States
  • GSK Investigational Site
    Jersey City, New Jersey 07304, United States
  • GSK Investigational Site
    The Bronx, New York 10461, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28277, United States
  • GSK Investigational Site
    Raleigh, North Carolina 28401, United States
  • GSK Investigational Site
    Rocky Mount, North Carolina 27804, United States
  • GSK Investigational Site
    Salisbury, North Carolina 28144, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Columbus, Ohio 43215, United States
  • GSK Investigational Site
    Dayton, Ohio 45417, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74136, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Portland, Oregon 97202, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Warwick, Rhode Island 02886, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406, United States
  • GSK Investigational Site
    Little River, South Carolina 29566, United States
  • GSK Investigational Site
    Mt. Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37938, United States
  • GSK Investigational Site
    Dallas, Texas 75231-4307, United States
  • GSK Investigational Site
    Houston, Texas 77074, United States
  • GSK Investigational Site
    Houston, Texas 77401, United States
  • GSK Investigational Site
    McKinney, Texas 75069, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84132, United States
  • GSK Investigational Site
    Norfolk, Virginia 23507, United States
  • GSK Investigational Site
    Williamsburg, Virginia 23188, United States
  • GSK Investigational Site
    Bellevue, Washington 68123, United States
  • GSK Investigational Site
    Bellingham, Washington 98225, United States
  • GSK Investigational Site
    Buenos Aires, C1406AGA, Argentina
  • GSK Investigational Site
    Buenos Aires, C199AAB, Argentina
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, C1128AAF, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1027AAP, Argentina
  • GSK Investigational Site
    Córdoba, X5003DCE, Argentina
  • GSK Investigational Site
    Mar del Plata, B7600FYK, Argentina
  • GSK Investigational Site
    Mendoza, 5500, Argentina
  • GSK Investigational Site
    Rosario, S2000DBS, Argentina
  • GSK Investigational Site
    Rosario, S2000DEJ, Argentina
  • GSK Investigational Site
    Rosario, S2002OJN, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, T4000IAI, Argentina
  • GSK Investigational Site
    Santa Fe, 3000, Argentina
  • GSK Investigational Site
    Vicente López, 1602, Argentina
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Ghent, 9000, Belgium
  • GSK Investigational Site
    Kortrijk, 8500, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Mechelen, 2800, Belgium
  • GSK Investigational Site
    Roeselare, 8800, Belgium
  • GSK Investigational Site
    Calgary, Alberta T2T 5C7, Canada
  • GSK Investigational Site
    Calgary, Alberta T3E 7M8, Canada
  • GSK Investigational Site
    Kelowna, British Columbia V1Y3H5, Canada
  • GSK Investigational Site
    Ajax, Ontario L1S 2J5, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8M 1K7, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5T 3A9, Canada
  • GSK Investigational Site
    Windsor, Ontario N8X 1T3, Canada
  • GSK Investigational Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • GSK Investigational Site
    Montreal, Quebec H1M 1B1, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Québec, Quebec G1N 4V3, Canada
  • GSK Investigational Site
    Québec, Quebec G1V 4G5, Canada

Showing the first 100 of 200 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Thach T, Dhanabalan K, Nandekar PP, Stauffer S, Heisler I, Alvarado S, Snyder J, Subramanian R. Mechanistic insights into the selective targeting of P2X3 receptor by camlipixant antagonist. J Biol Chem. 2025 Jan;301(1):108109. doi: 10.1016/j.jbc.2024.108109. Epub 2024 Dec 18. PubMed 39706278 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Dec 2025, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Oct 31, 2022
StartActual
Oct 25, 2022
Primary completionActual
Dec 17, 2025
CompletionActual
Jun 18, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05599191
Responsible party
Sponsor
First posted
Oct 31, 2022
Start date
Oct 25, 2022
Primary completion
Dec 17, 2025
Completion
Jun 18, 2026
Last update
Jul 14, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion